ReviewCardiovascular drugs and therapy2021
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Review in Cardiovascular drugs and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Efficacy and safety of Argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Argatroban-Associated Adverse Events: An Analysis Based on FDA Adverse Event Reporting System (FAERS).Cardiovascular toxicology · 2025Article
- Drug repurposing of argatroban, glimepiride and ranolazine shows anti-SARS-CoV-2 activity via diverse mechanisms.Heliyon · 2025Article
- Development of pharmacophore models for AcrB protein and the identification of potential adjuvant candidates for overcoming efflux-mediated colistin resistance.RSC medicinal chemistry · 2024Article
- The effect of argatroban on early neurological deterioration and outcomes in minor ischemic stroke: preliminary findings.Frontiers in neurology · 2024Article
- Gold single atom-based aptananozyme as an ultrasensitive and selective colorimetric probe for detection of thrombin and C-reactive protein.Mikrochimica acta · 2023Article
- COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation.Journal of clinical medicine · 2023Review
- Prospection of Peptide Inhibitors of Thrombin from Diverse Origins Using a Machine Learning Pipeline.Bioengineering (Basel, Switzerland) · 2023Article
- Update on Anticoagulation Strategies in Patients with ECMO-A Narrative Review.Journal of clinical medicine · 2023Review
- Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient.Anesthesiology · 2023Article
- Argatroban Resistance and Successful Adjunctive Anticoagulation for Cerebral Venous Sinus Thrombosis WithNeurology. Clinical practice · 2023Article
- Anticoagulation Management during Extracorporeal Membrane Oxygenation-A Mini-Review.Medicina (Kaunas, Lithuania) · 2022Review
- Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.The journal of extra-corporeal technology · 2022Article
- Green-Emitting 4,5-Diaminonaphthalimides in Activity-Based Probes for the Detection of Thrombin.Organic letters · 2022Article
- The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series.Journal of cardiothoracic and vascular anesthesia · 2022Article
- Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 Treatments.Genes · 2022Article
- Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.Chemical biology & drug design · 2022Article
- Parallel imaging of coagulation pathway proteases activated protein C, thrombin, and factor Xa in human plasma.Chemical science · 2022Article
- The enzymes in COVID-19: A review.Biochimie · 2022Review
- COVID-19 Presenting With a Challenging Combination of Thrombocytopenia and Thrombosis.Journal of medical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Thrombin is a trypsin-like serine protease with multiple physiological functions. Its role in coagulation and thrombosis is well-established. Nevertheless, thrombin also plays a major role in inflammation by activating protease-activated receptors. In addition, thrombin is also involved in angiogenesis, fibrosis, and viral infections. Considering the pathogenesis of COVID-19 pandemic, thrombin inhibitors may exert multiple potential therapeutic benefits including antithrombotic, anti-inflammatory, and antiviral activities. In this review, we describe the clinical features of COVID-19, the thrombin's roles in various pathologies, and the potential of argatroban in COVID-19 patients. Argatroban is a synthetic, small molecule, direct, competitive, and selective inhibitor of thrombin. It is approved to parenterally prevent and/or treat heparin-induced thrombocytopenia in addition to other thrombotic conditions. Argatroban also possesses anti-inflammatory and antiviral activities and has a well-established pharmacokinetics profile. It also appears to lack a significant risk of drug-drug interactions with therapeutics currently being evaluated for COVID-19. Thus, argatroban presents a substantial promise in treating severe cases of COVID-19; however, this promise is yet to be established in randomized, controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.